Can switching drugs outsmart breast cancer? new trial tests two targeted therapies
Disease control
Recruiting now
This phase 2 trial is testing two antibody-drug conjugates—trastuzumab deruxtecan (Enhertu) and datopotamab deruxtecan (Dato-DXd)—in people with HER2-negative metastatic breast cancer whose disease has worsened after prior antibody-drug conjugate therapy. Participants will receiv…
Phase: PHASE2 • Sponsor: Ana C Garrido-Castro, MD • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC